Matthew Powell, MD
Gynecologic Oncology · Saint Louis, MONPI 1609894187
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $117,344 of the $161,783 with a category attached, or 72.5%. 23 manufacturers reported payments, led by AstraZeneca at 25.9% of the total. Reporting peaked in 2019 at $62,544 and has fallen 84.8% since, to $9,528 in 2025. Among gynecologic oncology clinicians in MO with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 221 payments — averaging $732.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$42K
- Eisai Inc.$32K
- GSK$27K
- Merck$24K
- Tesaro, Inc.$13K
- Clovis Oncology, Inc.$6K
- plus $18K from 17 others
Across 27 payments — averaging $36,292 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$980K
- F. Hoffmann-la Roche AG$275
What the payments were for
- Consulting fees$117,34473%
- Speaking & faculty fees$32,19020%
- Grants$5000%
- Travel & lodging$4,4313%
- Food & beverage$7,3085%
- Education$110%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 54 | $41,880 |
| Eisai Inc. | 31 | $31,837 |
| GSK | 34 | $27,259 |
| Merck | 25 | $23,868 |
| Tesaro, Inc. | 15 | $13,180 |
| Clovis Oncology, Inc. | 18 | $6,162 |
| Aadi Bioscience, Inc. | 4 | $5,673 |
| Seagen Inc. | 4 | $3,830 |
| Biontech SE | 1 | $2,200 |
| Jazz Pharmaceuticals Inc. | 1 | $1,800 |
| Immunogen, Inc. | 2 | $1,479 |
| AbbVie | 6 | $618 |
| Genentech USA, Inc. | 5 | $428 |
| Intuitive Surgical | 4 | $324 |
| KARL Storz Endoscopy-america | 3 | $277 |
| Genmab U.S., Inc. | 5 | $272 |
| Corcept Therapeutics | 2 | $214 |
| Arthrex | 2 | $143 |
| Myriad Genetic Laboratories, Inc. | 1 | $142 |
| Novo Nordisk | 1 | $100 |
| Conmed Corporation | 1 | $56 |
| Karyopharm Therapeutics Inc. | 1 | $28 |
| EMD Serono, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$161,783 in reported general payments places this provider in the 90th percentile of 38 gynecologic oncology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LynparzaOlaparib | 18 | $191,884 |
| EliquisApixaban | 45 | $37,438 |
| XareltoRivaroxaban | 27 | $20,980 |
| Letrozole | 109 | $2,760 |
| Ondansetron Hcl | 94 | $1,505 |
| Colestipol Hcl | 23 | $1,140 |
| Prochlorperazine Maleate | 64 | $751 |
| Megestrol Acetate | 14 | $723 |
| Gabapentin | 90 | $668 |
| Dexamethasone | 64 | $648 |
| Clobetasol Propionate | 17 | $564 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 18 | $441 |
| Oxycodone Hcl | 50 | $361 |
| Bupropion XlBupropion Hcl | 26 | $276 |
| Levothyroxine Sodium | 38 | $258 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaLynparza | $41,880 | $191,88418 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 38 gynecologic oncology providers in Missouri.
Other gynecologic oncology in Saint Louis
- Premal ThakerSaint Louis$287K
- David MutchSaint Louis$26K
- Dan-Arin SilasiSaint Louis$23K
- Dineo KhabeleSaint Louis$22K
- Carolyn McCourtSaint Louis$14K
- Andrea HagemannSaint Louis$11K
- Shannon GraboschSaint Louis$9K
- Randall GibbSaint Louis$8K
- Leslie MassadSaint Louis$6K
- Madhavi ManyamSaint Louis$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.